



(12)发明专利申请

(10)申请公布号 CN 110396133 A

(43)申请公布日 2019.11.01

(21)申请号 201810376920.1

(22)申请日 2018.04.25

(71)申请人 中国科学院生物物理研究所
地址 100101 北京市朝阳区大屯路15号

(72)发明人 傅阳心 彭华 薛娣媛

(74)专利代理机构 北京市诚辉律师事务所
11430

代理人 唐宁

(51)Int.Cl.

C07K 19/00(2006.01)

C12N 15/62(2006.01)

C12N 15/85(2006.01)

A61K 38/20(2006.01)

A61P 35/00(2006.01)

权利要求书2页 说明书9页


序列表37页 附图13页

(54)发明名称

一种以白介素12为活性成分的融合蛋白型药物前体

(57)摘要

本发明涉及一种以白介素12为活性成分的融合蛋白型药物前体。所述融合蛋白型药物前体为同源或异源二聚体,二聚体中包括如下结构单元:(1)位于所述融合蛋白N端的第一结构单元:白介素12(IL-12)的一个或两个亚基,所述的白介素12的亚基为白介素12的P35亚基或P40亚基;(2)位于所述融合蛋白C端的第二结构单元:抗体Fc片段;(3)连接片段1:连接第一结构单元和第二结构单元或连接第一结构单元内部的两个亚基;以及可选的(4)通过能够被肿瘤微环境中特异性表达的蛋白水解酶识别并水解连接片段2连接的白介素12的受体结构单元。



1. 一种融合蛋白,其特征在于,所述融合蛋白包括:
 - (1) 位于所述融合蛋白N端的第一结构单元:白介素12 (IL-12) 的一个或两个亚基,所述的白介素12的亚基为白介素12的P35亚基或P40亚基;
 - (2) 位于所述融合蛋白C端的第二结构单元:抗体Fc片段;
 - (3) 连接片段1:连接第一结构单元和第二结构单元或连接第一结构单元内部的两个亚基。
2. 根据权利要求1所述的融合蛋白,其特征在于
所述的抗体Fc片段为人源IgG1,优选为人源Fc-knob或人源Fc-hole;
所述的P35亚基的氨基酸序列如Seq ID No.2所示,所述的P40亚基的氨基酸序列如Seq ID No.1所示;
所述的连接片段1的氨基酸序列如Seq ID No.9所示。
3. 根据权利要求1或2所述的融合蛋白,其特征在于,所述的融合蛋白还包括修饰在位于融合蛋白的N端的白介素12亚基的N端的信号肽,所述的信号肽为:
 - (1) 修饰在P35亚基N端的信号肽1,其氨基酸序列如Seq ID No.11所示;
 - 或(2) 修饰在P40亚基N端的信号肽2,其氨基酸序列如Seq ID No.12所示。
4. 根据权利要求1或2所述的融合蛋白,其特征在于,所述的融合蛋白还包括:
 - (4) 连接在第一结构单元N端的白介素12受体;
 - (5) 连接白介素12受体和第一结构单元的连接片段2。
5. 根据权利要求4所述的融合蛋白,其特征在于,
所述的白介素12受体为:IL-12RB1或IL-12RB2;
所述连接片段2能够被肿瘤微环境中特异性表达的蛋白水解酶识别并水解。
6. 根据权利要求5所述的融合蛋白,其特征在于:
所述的IL-12RB1的氨基酸序列如Seq ID No.6所示,所述的IL-12RB2的氨基酸序列如Seq ID No.7所示;
所述的肿瘤微环境中特异性表达的蛋白水解酶为基质金属蛋白酶,优选为基质金属蛋白酶14 (MMP14)。
7. 根据权利要求6所述的融合蛋白,其特征在于,
所述的连接片段2的氨基酸序列如Seq ID No.10所示,其被基质金属蛋白酶14识别的氨基酸的结构的序列如Seq ID No.8所示。
8. 根据权利要求1~7任一所述的融合蛋白,其特征在于,所述的融合蛋白中各个结构单元的排列方式为:
 - (1) 白介素12受体的C端与第一结构单元的N端通过连接片段2相连;
 - (2) 第一结构单元的C端与第二结构单元的N端通过连接片段1相连;
 - (3) 如第一结构单元内部有两个亚基,则第一亚基的C端和第二亚基的N端通过连接片段1相连。
9. 一种药物前体,所述的药物前体为同源或异源二聚体,其特征在于,构成所述的二聚体的单体任选自权利要求1~8任一所述的融合蛋白。
10. 根据权利要求9所述的药物前体,其特征在于,药物前体为如下药物前体1~7:
 - (1) 药物前体1 (Homo IL-12) 为同源二聚体,

组成的单体为:含有信号肽2的P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.13所示;

(2) 药物前体2 (Heter-IL-12) 为异源二聚体,

单体1为:含有信号肽2的P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.14所示;

单体2为:含有信号肽1的P35亚基、连接片段1、人源Fc-hole连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.15所示;

(3) 药物前体3 (Homo-R1) 为同源二聚体,

组成的单体为:IL-12的受体R β 1片段、连接片段2、P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.16所示;

(4) 药物前体4 (Homo-R2) 为同源二聚体,

组成的单体为:IL-12的受体R β 2片段、连接片段2、P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.17所示;

(5) 药物前体5 (Heter-R1/R2) 为异源二聚体,

单体1为:IL-12的受体R β 1片段、连接片段2、P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.18所示;

单体2为:IL-12的受体R β 2片段、连接片段2、P35亚基、连接片段1、人源Fc-hole依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.19所示;

(6) 药物前体6 (Heter-R1) 为异源二聚体,

单体1为:IL-12的受体R β 1片段、连接片段2、P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.20所示;

单体2为:含有信号肽1的P35亚基、连接片段1、人源Fc-hole依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.21所示;

(7) 药物前体7 (Heter-R2) 为异源二聚体,

单体1为:含有信号肽2的P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.22所示;

单体2为:IL-12的受体R β 2片段、连接片段2、P35亚基、连接片段1、人源Fc-hole连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.23所示。

11. 编码权利要求1~9任一所述的融合蛋白或药物前体的核苷酸片段。

12. 权利要求1~9任一所述的融合蛋白或药物前体在制备药物中的应用;优选的,所述的药物为抗肿瘤药物,最优选的,所述药物为抗结直肠癌的药物。

13. 权利要求1~9任一所述的融合蛋白、药物前体的制备方法,所述的制备方法包括如下步骤:

(1) 构建包含所述编码所述融合蛋白的编码基因的表达载体,优选的,所述的表达载体是pEE12.4表达载体;

(2) 通过瞬时转染宿主细胞的方法构建包含所述表达载体的宿主细胞,优选的,所述的宿主细胞是293F细胞;

(3) 培养所述宿主细胞并收集细胞上清;

(4) 通过ProteinA/G的亲和层析柱纯化蛋白纯化所述融合蛋白或药物前体。

一种以白介素12为活性成分的融合蛋白型药物前体

技术领域

[0001] 本发明属于医药生物领域,具体而言,涉及一种以白介素12为活性成分的融合蛋白型药物前体。

背景技术

[0002] 白细胞介素12(interleukin-12, IL-12)又名细胞毒淋巴细胞成熟因子(cytotoxic lymphocyte maturation factor, CLMF),也称为自然杀伤细胞刺激因子(natural killer cell stimulation factor, NKSF),是1989年发现的白细胞介素家族的成员。IL-12是一种异源二聚体细胞因子,由p35和p40两个亚基通过二硫键组成,主要由树突状细胞(DC)、巨噬细胞、单核细胞、B淋巴细胞以及其他抗原递呈细胞(APC)产生,能促进T辅助细胞1(Th1)的增殖;诱导NK细胞和T细胞产生 γ 干扰素;提高NK细胞的细胞毒作用;促进细胞毒性T细胞的形成等。

[0003] IL-12最初在1989年被鉴定为对外周血淋巴细胞具有多重生物学作用的天然杀伤(NK)细胞刺激因子【1】。IL-12主要由抗原呈递细胞(APC)如树突状细胞(DC),单核细胞,巨噬细胞和B细胞通过在Toll样受体相互作用下产生【2】因此,IL-12作为早期促炎细胞因子分泌以响应感染【3】。IL-12是分子量为70kDa的异二聚体,其由重(p40)和轻(p35)链亚基组成,其通过二硫键共价连接。p40可以通过吞噬细胞丰富地产生,但p35仅在低水平上普遍和组成型表达,需要与p40共表达才能分泌生物活性IL-12。在IL-12产生生物学效应的过程中p40仅发挥了媒介的作用,p35通过p40结合到细胞膜受体,两者通过由IL-12Rb1和IL-12Rb2组成的异二聚体IL-12受体(IL-12R)介导IL-12的信号传导【4】其中p35与IL-12Rb2的相互作用对向下传导信号至关重要,两个受体亚基的共表达是产生IL-12的高亲和力结合位点所必需的。p40亚基单独和受体结合可以竞争抑制IL-12的活性。在NK细胞,NK T细胞和活化的T细胞上发现IL-12R复合物【5】,同时也在髓系细胞【6】和扁桃体B细胞【7】上检测到。天然T细胞表达IL-12Rb1而不表达IL-12Rb2。在通过T细胞受体激活T细胞时,IL-12的两个受体都会被诱导,另外也会被IL-12本身,IFN γ ,肿瘤坏死因子- α (TNF- α)和抗CD28共刺激物另外增强【8】【9】。受体的成功触发激活了Janus激酶STAT(信号转导和转录激活子)信号通路,主要导致STAT4磷酸化,其介导随后的细胞反应【10】【11】。

[0004] IL12在固有免疫和适应性免疫的作用,通过连接先天和适应性免疫应答,IL-12在调节炎症中起关键作用。炎症环境下APC释放IL-12,导致NK和T细胞的随后的激活和增殖,有这些亚类在刺激时增加其IFN-g分泌,从而诱导IL-12治疗后观察到的大部分肿瘤抑制途径。对于抗肿瘤作用,一方面IL-12和IFN-g通过诱导细胞因子和细胞溶解因子如穿孔素和颗粒酶B【12】的转录来促进其效应子功能。另一方面分泌的IFN-g参与直接肿瘤血管反应,例如ICAM-1和VCAM-1的上调和血管发生的抑制。粘附分子上调有助于白细胞募集到肿瘤组织。此外IL-12将T细胞极化为1型辅助T(Th1)效应细胞表型。IL-12进一步显著促进Th1极化通过抑制2型辅助T细胞的发育过程【13】诱导的调节性T细胞(Tregs)和Th17细胞的分化。此外IL-12可以编辑效应T细胞,以最佳产生效应记忆T细胞和T滤泡辅助细胞【14】【15】也报道

了IL-12对APC的直接作用,增加了APC呈现差的免疫原性肿瘤抗原肽的能力【16】【17】。

[0005] 在临床前模型的使用中,IL12单独使用对肿瘤控制也很有效。Brunda【18】等人早在1993年就报道了B16黑素瘤,M5975肉瘤和RENCA肾细胞癌时腹腔注射重组IL-12的抗肿瘤反应。当肿瘤接种后的后期开始治疗时,也观察到IL-12的抗肿瘤作用,发现部分依赖于CD8T细胞。尽管IL-12的全身性给药显示出其作为实验性抗癌剂的巨大潜力,但是在推注给药之后,这种细胞因子的不稳定性和短的半衰期导致了应该研发将其直接递送到肿瘤部位的新方法。遵循这一策略,Vom Berg等人【19】运用渗透微量泵将IL-12局部递送到含有GL-261胶质瘤的小鼠的脑中。值得注意的是,IL-12与共抑制性受体细胞毒性T淋巴细胞抗原4(CTLA-4)的全身阻断的联合治疗在T细胞依赖的方式下在晚期疾病阶段消除了甚至非常后期的肿瘤。在此证据的基础上,结合IL-12与调控途径的靶向治疗具有很大的潜力来克服肿瘤相关免疫抑制。

[0006] IL-12在临床前模型中的有效抗肿瘤作用证明了将这种方法转化为临床使用的良好前景。但不幸的是,在临床试验中系统的i.v.重组IL-12的给药IL-12全身用药后不良反应较大,曾出现两例死于严重毒副作用的病人,且一般用药的病人会伴有如发热,胃肠道反应,淋巴细胞减少,肝功能异常等副作用,严重影响药物治疗效果【20】。

发明内容

[0007] 基于IL-12的上述问题和治疗潜力,在临床应用中,有必要对其进行更为有效和安全的进一步开发工作。

[0008] 本发明首先涉及一组融合蛋白,所述融合蛋白包括如下结构单元:

[0009] (1) 位于所述融合蛋白N端的第一结构单元:白介素12(IL-12)的一个或两个亚基,所述的白介素12的亚基为白介素12的P35亚基或P40亚基;

[0010] (2) 位于所述融合蛋白C端的第二结构单元:抗体Fc片段;

[0011] (3) 连接片段1:连接第一结构单元和第二结构单元或连接第一结构单元内部的两个亚基。

[0012] 其中,

[0013] 所述的抗体Fc片段为人源IgG1,优选为人源Fc-knob或人源Fc-hole;

[0014] 所述的P35亚基的氨基酸序列如Seq ID No.2所示,所述的P40亚基的氨基酸序列如Seq ID No.1所示;

[0015] 所述的连接片段1的氨基酸序列如Seq ID No.9所示。

[0016] 根据需要,本发明所述的融合蛋白还可以包括修饰在位于融合蛋白的N端的白介素12亚基的N端的信号肽,所述的信号肽为:

[0017] (1) 修饰在P35亚基N端的信号肽1,其氨基酸序列如Seq ID No.11所示;

[0018] 或(2) 修饰在P40亚基N端的信号肽2,其氨基酸序列如Seq ID No.12所示。

[0019] 所述的融合蛋白中各个结构单元的排列方式为:

[0020] (1) 第一结构单元的C端与第二结构单元的N端通过连接片段1相连;

[0021] (2) 如第一结构单元内部有两个亚基,则第一亚基的C端和第二亚基的N端通过连接片段1相连。

[0022] 本发明还涉及一种融合蛋白,包括如下结构单元:

[0023] (1) 位于所述融合蛋白N端的第一结构单元:白介素12(IL-12)的一个或两个亚基,所述的白介素12的亚基为白介素12的P35亚基或P40亚基;

[0024] (2) 位于所述融合蛋白C端的第二结构单元:抗体Fc片段;

[0025] (3) 连接片段1:连接第一结构单元和第二结构单元或连接第一结构单元内部的两个亚基;

[0026] (4) 连接在第一结构单元N端的白介素12受体;

[0027] (5) 连接白介素12受体和第一结构单元的连接片段2。

[0028] 其中,

[0029] 所述的抗体Fc片段为人源IgG1,优选为人源Fc-knob或人源Fc-hole;

[0030] 所述的P35亚基的氨基酸序列如Seq ID No.2所示,所述的P40亚基的氨基酸序列如Seq ID No.1所示;

[0031] 所述的连接片段1的氨基酸序列如Seq ID No.9所示;

[0032] 所述的白介素12受体为:IL-12Rβ1或IL-12Rβ2,所述的IL-12Rβ1的氨基酸序列如Seq ID No.6所示,所述的IL-12Rβ2的氨基酸序列如Seq ID No.7所示;

[0033] 所述连接片段2能够被肿瘤微环境中特异性表达的蛋白水解酶识别并水解,所述的肿瘤微环境中特异性表达的蛋白水解酶为基质金属蛋白酶,优选为基质金属蛋白酶14(MMP14)。

[0034] 最优的,所述的连接片段2的氨基酸序列如Seq ID No.10所示,其被基质金属蛋白酶14识别的氨基酸的结构的序列如Seq ID No.8所示。

[0035] 所述的融合蛋白中各个结构单元的排列方式为:

[0036] (1) 白介素12受体的C端与第一结构单元的N端通过连接片段2相连;

[0037] (2) 第一结构单元的C端与第二结构单元的N端通过连接片段1相连;

[0038] (3) 如第一结构单元内部有两个亚基,则第一亚基的C端和第二亚基的N端通过连接片段1相连。

[0039] 本发明还涉及一种药物前体,所述的药物前体为同源或异源二聚体,构成所述的二聚体的单体为所述的融合蛋白。

[0040] 优选的,所述的药物前体为如下药物前体1~7:

[0041] (1) 药物前体1(Homo IL-12)为同源二聚体,

[0042] 组成的单体为:含有信号肽2的P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.13所示;

[0043] (2) 药物前体2(Heter IL-12)为异源二聚体,

[0044] 单体1为:含有信号肽2的P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.14所示;

[0045] 单体2为:含有信号肽1的P35亚基、连接片段1、人源Fc-hole连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.15所示;

[0046] (3) 药物前体3(Homo-R1)为同源二聚体,

[0047] 组成的单体为:IL-12的受体Rβ1片段、连接片段2、P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.16所示;

[0048] (4) 药物前体4(Homo-R2)为同源二聚体,

[0049] 组成的单体为:IL-12的受体RB2片段、连接片段2、P40亚基、连接片段1、P35亚基、连接片段1、人源IgG1连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.17所示;

[0050] (5) 药物前体5 (Heter-R1/R2) 为异源二聚体,

[0051] 单体1为:IL-12的受体RB1片段、连接片段2、P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.18所示;

[0052] 单体2为:IL-12的受体RB2片段、连接片段2、P35亚基、连接片段1、人源Fc-hole依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.19所示;

[0053] (6) 药物前体6 (Heter-R1) 为异源二聚体,

[0054] 单体1为:IL-12的受体RB1片段、连接片段2、P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.20所示;

[0055] 单体2为:含有信号肽1的P35亚基、连接片段1、人源Fc-hole依次连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.21所示;

[0056] (7) 药物前体7 (Heter-R2) 为异源二聚体,

[0057] 单体1为:含有信号肽2的P40亚基、连接片段1、人源Fc-knob连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.22所示;

[0058] 单体2为:IL-12的受体RB2片段、连接片段2、P35亚基、连接片段1、人源Fc-hole连接成的融合蛋白,其氨基酸序列结构如SEQ ID No.23所示。

[0059] 本发明还涉及编码所述融合蛋白、所述药物前体的核苷酸片段。

[0060] 本发明还涉及所述融合蛋白、所述药物前体在制备药物中的应用;优选的,所述的药物为抗肿瘤药物,最优选的,所述药物为抗结直肠癌的药物。

[0061] 本发明还涉及所述的融合蛋白或药物前体的制备方法,所述的制备方法包括如下步骤:

[0062] (1) 构建包含所述编码所述融合蛋白或融合蛋白2或药物前体的编码基因的表达载体,优选的,所述的表达载体是pEE12.4表达载体;

[0063] (2) 通过瞬时转染宿主细胞的方法构建包含所述表达载体的宿主细胞,优选的,所述的宿主细胞是293F细胞;

[0064] (3) 培养所述宿主细胞并收集细胞上清;

[0065] (4) 通过ProteinA/G的亲和层析柱纯化蛋白纯化所述融合蛋白、融合蛋白2或药物前体。

附图说明

[0066] 图1、串联形式的IL-12-Fc二聚体prodrug:Homodimer-IL-12-Fc (Homo IL-12) 的结构示意图。

[0067] 图2、并联形式的IL-12-Fc二聚体prodrug:Heterdimer-IL-12-Fc (Heter IL-12) 的结构示意图,Fc-k是Fc-knob的简写,Fc-h是Fc-hole的简写。

[0068] 图3、Homodimer-IL-12-RB1二聚体prodrug (Homo-R1) 结构示意图。

[0069] 图4、Homodimer-IL-12-RB2二聚体prodrug (Homo-R2) 结构示意图。

[0070] 图5、Heterdimer-IL-12-RB1/RB2二聚体prodrug (Heter-R1/R2) 结构示意图,Fc-k是Fc-knob的简写,Fc-h是Fc-hole的简写。

[0071] 图6、Heterdimer-IL-12-R β 1二聚体prodrug (Heter-R1) 结构示意图, Fc-k是Fc-knob的简写, Fc-h是Fc-hole的简写。

[0072] 图7、Heterdimer-IL-12-R β 2二聚体prodrug (Heter-R2) 结构示意图, Fc-k是Fc-knob的简写, Fc-h是Fc-hole的简写。

[0073] 图8、图1~7所示的7种融合蛋白表达后的SDS-PAGE电泳鉴定图谱。

[0074] 图9、注射给药未连接IL-12受体的IL-12-Fc可以完全清除MC38肿瘤, 且Heter IL-12比Homo IL-12有更强的清除效果。

[0075] 图10、Heter IL-12的细胞毒性高于Homo IL-12。

[0076] 图11、Heter-R1, Heter-R2, Heter-R1/R2均可以有效地清除MC38肿瘤。

[0077] 图12、Heter IL-12连接IL-12受体的prodrug在系统性给药时有更小的毒副作用

具体实施方式

[0078] 实施例1、七种IL-12-Fc prodrug的设计

[0079] IL-12由p35和p40两个亚基组成, 选用humanIgG1、humanFc-knob、humanFc-hole的Fc片段构建相应的prodrug; 实际的prodrug的构建中, 我们选择将IL-12的两个亚基串联或并联, 具体形式如下:

[0080] 图1为, 两个亚基串联的IL-12的prodrug: Homodimer-IL-12-Fc (Homo IL-12) 的结构示意图, 二聚体的分子量为175KD (MW=175KD);

[0081] 图2为: 两个亚基并联的IL-12的prodrug: Heterdimer-IL-12-Fc (Heter IL-12) 的结构示意图, 二聚体的分子量为115KD (MW=115KD), 此二聚体中, P35和P40亚基的C端分别添加P35信号肽和P40信号肽。

[0082] 接下来, 我们通过阻断IL-12与其任意一受体的结合或者同时阻断其与两个受体的同时结合的方法来构建IL-12Prodrug; 截取IL-12R β 1与p40相互作用的N端两个CHR domain来阻断p40与IL-12R β 1的结合; 同时截取IL-12R β 2与p35相互作用的N端的一个Ig domain以及两个CHR domain来阻断p35与IL-12R β 2的结合。

[0083] 对于Homodimer-IL-12的prodrug构建如图3所示。

[0084] 图3为: Homodimer-IL-12-R β 1的prodrug结构示意图 (以下简称Homo-R1), 二聚体MW=232KD;

[0085] 图4为: Homodimer-IL-12-R β 2的prodrug结构示意图 (以下简称Homo-R2), 二聚体MW=250KD;

[0086] 图5为: Heterdimer-IL-12-R β 1/R β 2的prodrug结构示意图 (以下简称Heter-R1/R2), 二聚体MW=182KD;

[0087] 图6为: Heterdimer-IL-12-R β 1的prodrug结构示意图 (以下简称Heter-R1), 二聚体MW=144KD, 此二聚体中, P35-Fc-hole单体的融合片段P35的C端添加了P35信号肽;

[0088] 图7为: Heterdimer-IL-12-R β 2的prodrug结构示意图 (以下简称Heter-R2), 二聚体MW=153KD, 此二聚体中, P40-Fc-knob单体的融合片段P40的C端添加了P40信号肽。

[0089] 实施例2、IL-12prodrug的构建、纯化与生产

[0090] 我们对于实施例1所述的7种蛋白进行表达、生产, 首先在pEE12.4的表达载体上进行了融合蛋白的构建, 然后通过瞬时转染293F细胞的方法构建包含所述载体的宿主细胞,

培养所述宿主细胞并收集细胞上清,最后通过ProteinA/G的亲亲和层析柱纯化蛋白。

[0091] 对于同源二聚体蛋白的表达只需转入一种构建的表达载体质粒,细胞内表达的单体可以自发形成同源二聚体蛋白。对于异源二聚体蛋白的表达需转入摩尔比相同的两种表达载体质粒,细胞内表达的单体同样可以自发形成异源二聚体。

[0092] SDS-PAGE电泳鉴定图谱如图8所示:

[0093] 1、载体的构建、宿主细胞的转染及诱导表达

[0094] 1.1、我们在PEE12.4的载体上构建了各种融合蛋白的表达质粒,然后通过瞬时转染293F的方法获得各个蛋白的表达上清,最后通过Protein A亲和层析柱纯化了各种蛋白。

[0095] 构建表达载体

[0096] (1) PEE12.4-HindIII-p40 (signal) -NruI-p35 (no signal) -BsiWI-hIgG1-EcoRI

[0097] (2) PEE12.4-HindIII-P35 (signal) -BsiWI-Fch-EcoRI

[0098] (3) PEE12.4-HindIII-P40 (signal) -NruI-Fck-EcoRI

[0099] (4) PEE12.4-HindIII-IL12Rb1/IL12Rb2-BsiWI-p40 (no signal) -NruI-p35 (no signal) -BsiWI

[0100] -hIgG1-EcoRI

[0101] (5) PEE12.4-HindIII-IL12Rb1-BsiWI-p40 (no signal) -NruI-Fck-EcoRI

[0102] (6) PEE12.4-HindIII-IL12Rb2-BstBI-p35 (no signal) -BsiWI-Fch-EcoRI

[0103] 其中,HindIII、NruI、BsiWI、EcoRI为酶切位点。

[0104] 各个融合蛋白片段间的连接序列为:

[0105] (1) homo IL-12:P40和P35之间为

[0106] (2) linker1,P35和Fc之间为linker1;

[0107] (2) heter IL-12:P40和Fc之间为linker1,P35和Fc之间为linker1;

[0108] (3) RB1与P40之间为linker2;相应的蛋白酶的酶切靶序列为SGRSENIRTA;

[0109] (4) RB2与P40之间为linker2;相应的蛋白酶的酶切靶序列为SGRSENIRTA;

[0110] (5) RB2与P35之间为linker2;相应的蛋白酶的酶切靶序列为SGRSENIRTA;

[0111] 1.2、瞬时转染快速表达目的蛋白:

[0112] (1) 细胞复苏:Freestyle 293F细胞以 3×10^7 cells/ml的浓度于CD OptiCHOTM media (含10% DMSO) 中冻存。从液氮中取出后在37°C水浴锅中快速溶化,加入到含有10ml OptiCHOTM media的15ml离心管中离心,1,000rpm,5min。弃上清,将细胞沉淀悬浮培养于30ml OptiCHOTM media中,37°C,8%CO₂,135rpm。4天后将细胞进行扩大培养,扩大培养时浓度不要超过 3×10^6 cells/ml。

[0113] (2) 转染前两天,准备悬浮培养的293F细胞用于瞬时转染(200ml),接种密度为 $0.6-0.8 \times 10^6$ cells/ml。

[0114] (3) 两天后对待转染细胞悬液进行计数,预计细胞密度 $2.5-3.5 \times 10^6$ cells/ml,随后取细胞悬液1,000rpm离心5min,弃上清。

[0115] (4) 用50ml的新鲜的Freestyle 293media重新悬浮细胞,再次1,000rpm离心5min,弃上清液。

[0116] (5) 用200ml Freestyle 293media重新悬浮293F细胞。

[0117] (6) 用5ml Freestyle 293media培养基稀释600μg质粒,并利用0.22μm滤器过滤除

菌。

[0118] (7) 用5ml Freestyle 293media培养基稀释1.8mg PEI并利用0.22μM滤器过滤除菌。随后立即将5ml质粒和5ml的PEI混匀,室温静置5分钟。

[0119] (8) 将质粒/PEI混合物加入细胞悬液中,放置在37℃,8%CO₂,85rpm培养箱中培养,同时补加生长因子50ug/L LONGTMR3IGF-1。

[0120] (9) 4小时后补加200ml EX-CELLTM 293media培养基和2mM Glutamine,将转速调至135rpm继续培养。

[0121] (10) 24小时后加入细胞增殖抑制剂3.8mM VPA,72小时后加入40ml medium D继续培养,转然后6-8天(细胞存活率低于70%)收集上清液进行下一步纯化。

[0122] 1.3、融合蛋白的收集、纯化和电泳验证

[0123] 利用Protein A进行目的蛋白纯化

[0124] (1) 样品准备:将悬浮细胞培养液转至500ml离心桶中离心,8,000rpm,20min弃沉淀,将上清经0.45μM滤器过滤除去杂质,然后加入终浓度为0.05%NaN₃防止纯化过程中细菌污染。

[0125] (2) 组装层析柱:取适量Protein A Agarose(每1ml Protein A纯化20mg human Fc融合蛋白计算)混匀后加入层析柱,室温静置约10min,待Protein A与20%乙醇溶液分层后把底部的出口打开,让乙醇溶液通过重力作用缓慢流出。

[0126] (3) 分别用10倍柱体积的蒸馏水和Binding buffer(20mM sodium phosphate+0.15M NaCl,pH 7.0)冲洗和平衡层析柱。

[0127] (4) 利用恒流泵进行上样,流速为10倍柱体积/小时,收集流穿液,重复上样2次。

[0128] (5) 用10倍柱体积以上的Binding buffer冲洗柱子,洗去杂蛋白,冲洗至流出液无蛋白检出。

[0129] (6) 使用Elution Buffer(0.1M Glycine,pH 2.7)进行洗脱,洗脱液分管收集,每1ml收集1管,并采用蛋白指示液(Bio-Rad protein assay)观察洗脱峰。将洗脱峰的收集管混合后加入适量的1M Tris,pH 9.0中和(调节pH值至6-8,应于所纯化蛋白等电点相差0.5以上)。

[0130] (7) 利用Zeba脱盐离心柱或浓缩离心柱将目的蛋白溶液置换到所需要的缓冲液中(注意调节缓冲液pH,避开蛋白的等电点)。利用BSA为标准品,通过SDS-PAGE电泳(每个样品的蛋白上样量为2.5ug)和NanoDrop2000确定蛋白浓度。

[0131] 洗脱结束后,依次使用20倍柱体积的蒸馏水冲洗柱子,再用10倍柱体积的20%乙醇冲洗柱子,最后乙醇溶液要浸没凝胶介质,4℃保存。

[0132] 实施例3、各融合蛋白的体内抗肿瘤活性

[0133] 1、系统性注射IL-12-Fc可以完全清除MC38肿瘤,并且Heter IL-12的治疗效果比Homo IL-12更好

[0134] 为了确定我们设计并生产的IL-12-Fc在系统性给药时是否能够有效地清除肿瘤并且比较两种形式的IL-12-Fc的治疗效果。我们在MC38模型中通过系统性给药的方式对小鼠进行不同剂量的治疗。试验结果如图9所示:

[0135] 图9A:WT C57BL/6小鼠(n=5只/组)在第0天时皮下接种5x10⁵个MC38细胞。第13,16,20天时腹腔注射PBS,0.5ug,1ug,5ug,10ug的Homo IL-12治疗,记录荷瘤小鼠的肿瘤体

积。

[0136] 图9B:WT C57BL/6小鼠 (n=5只/组) 在第0天时皮下接种 5×10^5 个MC38细胞。第13, 16, 20天时腹腔注射PBS, 0.5ug, 1ug, 5ug, 10ug的Heter IL-12治疗, 记录荷瘤小鼠的肿瘤体积。

[0137] 这项结果表明IL-12-Fc能够有效的清除肿瘤并且Heter IL-12比Homo IL-12对肿瘤有更好的清除。

[0138] 2、IL-12-Fc的系统性使用会引发严重的毒副作用且Heter IL-12毒性高于Homo IL-12

[0139] 由于IL-12的受体广泛存在于T, B, NK细胞, 所以IL-12的使用常常伴随着很强的毒副作用, 临床上病人主要表现为各种血液疾病和肝脏毒性等。我们进一步检测了IL-12-Fc的毒性, 主要检测指标是小鼠血清中各种炎症细胞因子的含量。

[0140] 取WT C57BL/6小鼠 (n=5只/组), 在第0天时皮下接种 5×10^5 个MC38细胞; 第13, 16, 20天时腹腔注射PBS, 5ug的Homo IL-12或Heter IL-12治疗, 在第20天给药治疗后6h, 眼静脉取血检测血清中炎症因子IL-12p70, IFN γ , TNF, MCP-1, IL-10, IL-6的含量。

[0141] 结果如图10所示, Homo IL-12与Heter IL-12均会引发强的细胞毒性, 且Heter IL-12的细胞毒性高于Homo IL-12。

[0142] 3、Heter IL-12连接IL-12受体的prodrug可以有效地清除MC38肿瘤

[0143] 我们构建IL-12prodrug, 通过肿瘤微环境中特异性表达的蛋白水解酶的底物来连接IL-12Receptor与IL-12, 目的是通过肿瘤微环境中特异性的蛋白水解酶将IL-12prodrug中的底物特异性的在肿瘤微环境被切开, 增加IL-12使用的靶向性也降低IL-12全身性使用时的毒性。通过之前体内实验探究我们确定当使用量小于5ug/小鼠时, Heter IL-12比Homo IL-12对MC38肿瘤有更好的清除效果, 但同时有更强的毒性。所以我们使用实施例1所述的Heter IL-12以不同方式连接IL-12受体的前药 (prodrug) 即Heter-R1, Heter-R2, Heter-R1/R2; 以及Homo IL-12以不同方式连接IL-12受体的前药 (prodrug) 即Homo-R1, Homo-R2, 来测试prodrug的体内效果。

[0144] 图11A:WT C57BL/6小鼠 (n=5只/组) 在第0天时皮下接种 5×10^5 个MC38细胞, 第10, 13, 16天时腹腔注射5ug的Heter IL-12, Heter-R1, Heter-R2, Heter-R1/R2或Homo-R2治疗, 对照组为PBS。

[0145] 图11B:WT C57BL/6小鼠 (n=5只/组) 在第0天时皮下接种 5×10^5 个MC38细胞。第10, 13, 16天时腹腔注射2.5ug的Heter IL-12, Heter-R1, Heter-R2或Heter-R1/R2治疗, 对照组为PBS。

[0146] 实验结果表明, 三种形式的Heter IL-12的前药 (prodrug) 均可以有效地清除肿瘤, 给药剂量为5ug/小鼠时, Heter IL-12的三种形式的前药比Homo IL-12的前药对MC38有更好的清除效果, 将剂量降低一倍即2.5ug/小鼠, Heter IL-12prodrug (Heter R1, Heter R2或Heter-R1/R2) 仍然可以有效的清除肿瘤。

[0147] 4、Heter IL-12连接IL-12受体的prodrug在系统性给药时有更小的毒副作用

[0148] 根据前述实验结果, 已知未偶联IL-12受体的IL-12-Fc在系统性给药时可以引发严重的毒副作用, 因此我们记录了连接IL-12受体的不同形式的Heter IL-12prodrug在系统性给药后小鼠体重的波动情况, 并且通过小鼠的眼静脉取血检测了血清中炎症因子的表

达水平。

[0149] 图12A:WT C57BL/6小鼠 (n=5只/组) 在第0天时皮下接种 5×10^5 个MC38细胞,第10,13,16天时腹腔注射2.5ug的Heter IL-12、Heter R1、Heter R2、Heter R1/R2治疗,对照组为PBS,在治疗的同时测量小鼠体重。

[0150] 图12B-G:治疗同时进行小鼠眼静脉取血,检测血清中炎症因子IL-12p70,TNF,IFN γ ,MCP-1,IL-10,IL-6的含量。

[0151] 实验结果表明,在剂量为2.5ug/小鼠系统性给药时,Heter IL-12以不同形式连接IL-12受体的prodrug (Heter R1、Heter R2) 相较于未连接IL-12受体的Heter IL-12而言,有更小的毒副作用,并且Heter-R2相较于其他类型的prodrug有更小的毒性。

[0152] 综合上述实施例,在mouse MC38模型中,连接IL-12受体的IL-12-Fc的prodrug可以保持抗肿瘤的有效性和并且提高IL-12-Fc使用过程的安全性。低剂量(2.5ug)的连接了IL-12受体的Heter IL-12前药可以完全清除肿瘤体积为130-150mm³的Mc38肿瘤,并且肿瘤不会复发。当对比同样剂量的未连接IL-12受体的IL-12-Fc时,前者在系统性注射的过程中产生更小的毒副作用,一方面体现在小鼠体重不会明显降低,另一方面体现在连接了IL-12受体的Heter IL-12引发的血液中炎症因子表达水平更低,尤其是Heter R2的应用更加安全。

[0153] 最后需要说明的是,以上实施例仅用作帮助本领域技术人员理解本发明的实质,不用做对本发明保护范围的限定。

SEQUENCE LISTING

<110> 中国科学院生物物理研究所

<120> 一种以白介素12为活性成分的融合蛋白型药物前体

<130> CP11802086C

<160> 23

<170> PatentIn version 3.3

<210> 1

<211> 313

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Trp Glu Leu Glu Lys Asp Val Tyr Val Val Glu Val Asp Trp Thr
1           5           10           15
Pro Asp Ala Pro Gly Glu Thr Val Asn Leu Thr Cys Asp Thr Pro Glu
           20           25           30
Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln Arg His Gly Val Ile Gly
           35           40           45
Ser Gly Lys Thr Leu Thr Ile Thr Val Lys Glu Phe Leu Asp Ala Gly
           50           55           60
Gln Tyr Thr Cys His Lys Gly Gly Glu Thr Leu Ser His Ser His Leu
65           70           75           80
Leu Leu His Lys Lys Glu Asn Gly Ile Trp Ser Thr Glu Ile Leu Lys
           85           90           95
Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys Glu Ala Pro Asn Tyr Ser
           100          105          110
Gly Arg Phe Thr Cys Ser Trp Leu Val Gln Arg Asn Met Asp Leu Lys
           115          120          125
Phe Asn Ile Lys Ser Ser Ser Ser Ser Pro Asp Ser Arg Ala Val Thr
           130          135          140
Cys Gly Met Ala Ser Leu Ser Ala Glu Lys Val Thr Leu Asp Gln Arg
145          150          155          160
Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln Glu Asp Val Thr Cys Pro
           165          170          175
Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu Ala Leu Glu Ala Arg Gln
           180          185          190
Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser Phe Phe Ile Arg Asp Ile
           195          200          205
Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln Met Lys Pro Leu Lys Asn

```

210	215	220
Ser Gln Val Glu Val Ser Trp Glu Tyr Pro Asp Ser Trp Ser Thr Pro		
225	230	235
His Ser Tyr Phe Ser Leu Lys Phe Phe Val Arg Ile Gln Arg Lys Lys		
	245	250
Glu Lys Met Lys Glu Thr Glu Glu Gly Cys Asn Gln Lys Gly Ala Phe		
	260	265
Leu Val Glu Lys Thr Ser Thr Glu Val Gln Cys Lys Gly Gly Asn Val		
	275	280
Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn Ser Ser Cys Ser Lys Trp		
290	295	300
Ala Cys Val Pro Cys Arg Val Arg Ser		
305	310	
<210> 2		
<211> 193		
<212> PRT		
<213> Homo sapiens		
<400> 2		
Arg Val Ile Pro Val Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg		
1	5	10
Asn Leu Leu Lys Thr Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys		
	20	25
Leu Lys His Tyr Ser Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile		
	35	40
Thr Arg Asp Gln Thr Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu		
	50	55
His Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr		
65	70	75
Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu		
	85	90
Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe		
	100	105
Gln Ala Ile Asn Ala Ala Leu Gln Asn His Asn His Gln Gln Ile Ile		
	115	120
Leu Asp Lys Gly Met Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu		
	130	135
Asn His Asn Gly Glu Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala		
145	150	155
Asp Pro Tyr Arg Val Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe		

				165					170					175			
Ser	Thr	Arg	Val	Val	Thr	Ile	Asn	Arg	Val	Met	Gly	Tyr	Leu	Ser	Ser		
			180					185					190				
Ala																	
<210>	3																
<211>	227																
<212>	PRT																
<213>	Homo sapiens																
<400>	3																
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly		
1			5					10					15				
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met		
			20					25					30				
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His		
			35					40					45				
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val		
			50				55				60						
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr		
65						70				75					80		
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly		
			85					90						95			
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile		
			100					105						110			
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val		
			115					120						125			
Cys	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser		
			130					135						140			
Leu	Ser	Cys	Ala	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu		
			145					150						155			160
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro		
			165											170			175
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Val	Ser	Lys	Leu	Thr	Val		
			180											185			190
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met		
			195					200						205			
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser		
			210					215						220			
Pro	Gly	Lys															
			225														

<210> 4
 <211> 227
 <212> PRT
 <213> Homo sapiens
 <400> 4
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 1 5 10 15
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 20 25 30
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 35 40 45
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 50 55 60
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 65 70 75 80
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 85 90 95
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 100 105 110
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 115 120 125
 Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 130 135 140
 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 145 150 155 160
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 165 170 175
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 180 185 190
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 195 200 205
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 210 215 220
 Pro Gly Lys
 225
 <210> 5
 <211> 226
 <212> PRT
 <213> Homo sapiens

<400> 5

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 1 5 10 15
 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met
 20 25 30
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 35 40 45
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 50 55 60
 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 65 70 75 80
 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 85 90 95
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 100 105 110
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 115 120 125
 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 130 135 140
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 145 150 155 160
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 165 170 175
 Val Leu Asp Ser Asp Gly Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp
 180 185 190
 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His
 195 200 205
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 210 215 220

Gly Lys

225

<210> 6

<211> 259

<212> PRT

<213> Homo sapiens

<400> 6

Met Asp Met Met Gly Leu Ala Gly Thr Ser Lys His Ile Thr Phe Leu
 1 5 10 15
 Leu Leu Cys Gln Leu Gly Ala Ser Gly Pro Gly Asp Gly Cys Cys Val

20	25	30
Glu Lys Thr Ser Phe Pro	Glu Gly Ala Ser Gly Ser	Pro Leu Gly Pro
35	40	45
Arg Asn Leu Ser Cys Tyr Arg	Val Ser Lys Thr Asp Tyr	Glu Cys Ser
50	55	60
Trp Gln Tyr Asp Gly Pro	Glu Asp Asn Val Ser His	Val Leu Trp Cys
65	70	75
Cys Phe Val Pro Pro Asn His	Thr His Thr Gly Gln Glu	Arg Cys Arg
85	90	95
Tyr Phe Ser Ser Gly Pro	Asp Arg Thr Val Gln Phe	Trp Glu Gln Asp
100	105	110
Gly Ile Pro Val Leu Ser	Lys Val Asn Phe Trp Val	Glu Ser Arg Leu
115	120	125
Gly Asn Arg Thr Met Lys	Ser Gln Lys Ile Ser Gln	Tyr Leu Tyr Asn
130	135	140
Trp Thr Lys Thr Thr Pro	Pro Leu Gly His Ile Lys	Val Ser Gln Ser
145	150	155
His Arg Gln Leu Arg Met	Asp Trp Asn Val Ser Glu	Glu Ala Gly Ala
165	170	175
Glu Val Gln Phe Arg Arg	Arg Met Pro Thr Thr	Asn Trp Thr Leu Gly
180	185	190
Asp Cys Gly Pro Gln Val	Asn Ser Gly Ser Gly Val	Leu Gly Asp Ile
195	200	205
Arg Gly Ser Met Ser Glu	Ser Cys Leu Cys Pro Ser	Glu Asn Met Ala
210	215	220
Gln Glu Ile Gln Ile Arg	Arg Arg Arg Arg Leu	Ser Ser Gly Ala Pro
225	230	235
Gly Gly Pro Trp Ser Asp	Trp Ser Met Pro Val	Cys Val Pro Pro Glu
245	250	255
Val Leu Pro		
<210> 7		
<211> 337		
<212> PRT		
<213> Homo sapiens		
<400> 7		
Met Ala Gln Thr Val Arg	Glu Cys Ser Leu Ala	Leu Leu Phe Leu Phe
1	5	10
Met Trp Leu Leu Ile Lys	Ala Asn Ile Asp Val	Cys Lys Leu Gly Thr
20	25	30

Val Thr Val Gln Pro Ala Pro Val Ile Pro Leu Gly Ser Ala Ala Asn
 35 40 45
 Ile Ser Cys Ser Leu Asn Pro Lys Gln Gly Cys Ser His Tyr Pro Ser
 50 55 60
 Ser Asn Glu Leu Ile Leu Leu Lys Phe Val Asn Asp Val Leu Val Glu
 65 70 75 80
 Asn Leu His Gly Lys Lys Val His Asp His Thr Gly His Ser Ser Thr
 85 90 95
 Phe Gln Val Thr Asn Leu Ser Leu Gly Met Thr Leu Phe Val Cys Lys
 100 105 110
 Leu Asn Cys Ser Asn Ser Gln Lys Lys Pro Pro Val Pro Val Cys Gly
 115 120 125
 Val Glu Ile Ser Val Gly Val Ala Pro Glu Pro Pro Gln Asn Ile Ser
 130 135 140
 Cys Val Gln Glu Gly Glu Asn Gly Thr Val Ala Cys Ser Trp Asn Ser
 145 150 155 160
 Gly Lys Val Thr Tyr Leu Lys Thr Asn Tyr Thr Leu Gln Leu Ser Gly
 165 170 175
 Pro Asn Asn Leu Thr Cys Gln Lys Gln Cys Phe Ser Asp Asn Arg Gln
 180 185 190
 Asn Cys Asn Arg Leu Asp Leu Gly Ile Asn Leu Ser Pro Asp Leu Ala
 195 200 205
 Glu Ser Arg Phe Ile Val Arg Val Thr Ala Ile Asn Asp Leu Gly Asn
 210 215 220
 Ser Ser Ser Leu Pro His Thr Phe Thr Phe Leu Asp Ile Val Ile Pro
 225 230 235 240
 Leu Pro Pro Trp Asp Ile Arg Ile Asn Phe Leu Asn Ala Ser Gly Ser
 245 250 255
 Arg Gly Thr Leu Gln Trp Glu Asp Glu Gly Gln Val Val Leu Asn Gln
 260 265 270
 Leu Arg Tyr Gln Pro Leu Asn Ser Thr Ser Trp Asn Met Val Asn Ala
 275 280 285
 Thr Asn Ala Lys Gly Lys Tyr Asp Leu Arg Asp Leu Arg Pro Phe Thr
 290 295 300
 Glu Tyr Glu Phe Gln Ile Ser Ser Lys Leu His Leu Ser Gly Gly Ser
 305 310 315 320
 Trp Ser Asn Trp Ser Glu Ser Leu Arg Thr Arg Thr Pro Glu Glu Glu
 325 330 335
 Pro

<210> 8

<211> 10

<212> PRT

<213> 人工序列

<400> 8

Ser Gly Arg Ser Glu Asn Ile Arg Thr Ala

1 5 10

<210> 9

<211> 15

<212> PRT

<213> 人工序列

<400> 9

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10 15

<210> 10

<211> 20

<212> PRT

<213> 人工序列

<400> 10

Gly Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg Thr Ala Gly

1 5 10 15

Gly Gly Gly Ser

20

<210> 11

<211> 22

<212> PRT

<213> 人工序列

<400> 11

Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu

1 5 10 15

Asn His Leu Ser Leu Ala

20

<210> 12

<211> 22

<212> PRT

<213> 人工序列

<400> 12

Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu

1 5 10 15

Val Ser Pro Leu Met Ala
 20
 <210> 13
 <211> 784
 <212> PRT
 <213> 人工序列
 <400> 13
 Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu
 1 5 10 15
 Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val
 20 25 30
 Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu
 35 40 45
 Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln
 50 55 60
 Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys
 65 70 75 80
 Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr
 85 90 95
 Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp
 100 105 110
 Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys
 115 120 125
 Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln
 130 135 140
 Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Pro
 145 150 155 160
 Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys
 165 170 175
 Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln
 180 185 190
 Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu
 195 200 205
 Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser
 210 215 220
 Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln
 225 230 235 240
 Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro
 245 250 255

Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val
 260 265 270
 Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys
 275 280 285
 Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln
 290 295 300
 Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn
 305 310 315 320
 Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly
 325 330 335
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Arg Val
 340 345 350
 Ile Pro Val Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg Asn Leu
 355 360 365
 Leu Lys Thr Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys Leu Lys
 370 375 380
 His Tyr Ser Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile Thr Arg
 385 390 395 400
 Asp Gln Thr Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu His Lys
 405 410 415
 Asn Glu Ser Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr Arg Gly
 420 425 430
 Ser Cys Leu Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu Cys Leu
 435 440 445
 Gly Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe Gln Ala
 450 455 460
 Ile Asn Ala Ala Leu Gln Asn His Asn His Gln Gln Ile Ile Leu Asp
 465 470 475 480
 Lys Gly Met Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu Asn His
 485 490 495
 Asn Gly Glu Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala Asp Pro
 500 505 510
 Tyr Arg Val Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe Ser Thr
 515 520 525
 Arg Val Val Thr Ile Asn Arg Val Met Gly Tyr Leu Ser Ser Ala Gly
 530 535 540
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Asp Lys
 545 550 555 560
 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro

	565	570	575
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser			
	580	585	590
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp			
	595	600	605
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn			
	610	615	620
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val			
625	630	635	640
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu			
	645	650	655
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys			
	660	665	670
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr			
	675	680	685
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr			
	690	695	700
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu			
705	710	715	720
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu			
	725	730	735
Asp Ser Asp Gly Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser			
	740	745	750
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala			
	755	760	765
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys			
	770	775	780
<210> 14			
<211> 577			
<212> PRT			
<213> 人工序列			
<400> 14			
Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu			
1	5	10	15
Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val			
	20	25	30
Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu			
	35	40	45
Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln			

50	55	60
Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys		
65	70	75
Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr		
	85	90
Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp		
	100	105
Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys Cys		
	115	120
Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln		
	130	140
Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Pro		
145	150	155
Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys		
	165	170
Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln		
	180	185
Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu		
	195	200
Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser		
	210	220
Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln		
225	230	235
Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro		
	245	250
Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val		
	260	265
Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys		
	275	280
Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln		
	290	295
Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn		
305	310	315
Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly		
	325	330
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys		
	340	345
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro		
	355	360
		365

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
 370 375 380
 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
 385 390 395 400
 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
 405 410 415
 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
 420 425 430
 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
 435 440 445
 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
 450 455 460
 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
 465 470 475 480
 Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp
 485 490 495
 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
 500 505 510
 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
 515 520 525
 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
 530 535 540
 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
 545 550 555 560
 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 565 570 575

Lys

<210> 15

<211> 457

<212> PRT

<213> 人工序列

<400> 15

Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu
 1 5 10 15
 Asn His Leu Ser Leu Ala Arg Val Ile Pro Val Ser Gly Pro Ala Arg
 20 25 30
 Cys Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val
 35 40 45
 Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp

50	Ile Asp His Glu Asp	55	Ile Thr Arg Asp Gln Thr Ser Thr Leu Lys Thr	60	
65		70		75	80
	Cys Leu Pro Leu Glu		Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg		
		85		90	95
	Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr				
		100		105	110
	Ser Leu Met Met Thr Leu Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys				
		115		120	125
	Met Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala Ala Leu Gln Asn His				
		130		135	140
	Asn His Gln Gln Ile Ile Leu Asp Lys Gly Met Leu Val Ala Ile Asp				
		145		150	155
	Glu Leu Met Gln Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gln Lys				
		165		170	175
	Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys				
		180		185	190
	Ile Leu Leu His Ala Phe Ser Thr Arg Val Val Thr Ile Asn Arg Val				
		195		200	205
	Met Gly Tyr Leu Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly				
		210		215	220
	Ser Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro				
		225		230	235
	Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys				
		245		250	255
	Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val				
		260		265	270
	Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr				
		275		280	285
	Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu				
		290		295	300
	Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His				
		305		310	315
	Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys				
		325		330	335
	Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln				
		340		345	350
	Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu				
		355		360	365

Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro
 370 375 380
 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 385 390 395 400
 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 405 410 415
 Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 420 425 430
 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 435 440 445
 Lys Ser Leu Ser Leu Ser Pro Gly Lys
 450 455
 <210> 16
 <211> 1041
 <212> PRT
 <213> 人工序列
 <400> 16
 Met Asp Met Met Gly Leu Ala Gly Thr Ser Lys His Ile Thr Phe Leu
 1 5 10 15
 Leu Leu Cys Gln Leu Gly Ala Ser Gly Pro Gly Asp Gly Cys Cys Val
 20 25 30
 Glu Lys Thr Ser Phe Pro Glu Gly Ala Ser Gly Ser Pro Leu Gly Pro
 35 40 45
 Arg Asn Leu Ser Cys Tyr Arg Val Ser Lys Thr Asp Tyr Glu Cys Ser
 50 55 60
 Trp Gln Tyr Asp Gly Pro Glu Asp Asn Val Ser His Val Leu Trp Cys
 65 70 75 80
 Cys Phe Val Pro Pro Asn His Thr His Thr Gly Gln Glu Arg Cys Arg
 85 90 95
 Tyr Phe Ser Ser Gly Pro Asp Arg Thr Val Gln Phe Trp Glu Gln Asp
 100 105 110
 Gly Ile Pro Val Leu Ser Lys Val Asn Phe Trp Val Glu Ser Arg Leu
 115 120 125
 Gly Asn Arg Thr Met Lys Ser Gln Lys Ile Ser Gln Tyr Leu Tyr Asn
 130 135 140
 Trp Thr Lys Thr Thr Pro Pro Leu Gly His Ile Lys Val Ser Gln Ser
 145 150 155 160
 His Arg Gln Leu Arg Met Asp Trp Asn Val Ser Glu Glu Ala Gly Ala
 165 170 175

Glu Val Gln Phe Arg Arg Arg Met Pro Thr Thr Asn Trp Thr Leu Gly
 180 185 190
 Asp Cys Gly Pro Gln Val Asn Ser Gly Ser Gly Val Leu Gly Asp Ile
 195 200 205
 Arg Gly Ser Met Ser Glu Ser Cys Leu Cys Pro Ser Glu Asn Met Ala
 210 215 220
 Gln Glu Ile Gln Ile Arg Arg Arg Arg Arg Leu Ser Ser Gly Ala Pro
 225 230 235 240
 Gly Gly Pro Trp Ser Asp Trp Ser Met Pro Val Cys Val Pro Pro Glu
 245 250 255
 Val Leu Pro Gly Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg
 260 265 270
 Thr Ala Gly Gly Gly Gly Ser Met Trp Glu Leu Glu Lys Asp Val Tyr
 275 280 285
 Val Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn
 290 295 300
 Leu Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp
 305 310 315 320
 Gln Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val
 325 330 335
 Lys Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu
 340 345 350
 Thr Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile
 355 360 365
 Trp Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys
 370 375 380
 Cys Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val
 385 390 395 400
 Gln Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser
 405 410 415
 Pro Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu
 420 425 430
 Lys Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys
 435 440 445
 Gln Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu
 450 455 460
 Leu Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr
 465 470 475 480
 Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu

	485	490	495
Gln Met Lys Pro Leu Lys Asn Ser	Gln Val Glu Val Ser Trp Glu Tyr		
	500	505	510
Pro Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe			
	515	520	525
Val Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly			
	530	535	540
Cys Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val			
545	550	555	560
Gln Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr			
	565	570	575
Asn Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser			
	580	585	590
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg			
	595	600	605
Val Ile Pro Val Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg Asn			
	610	615	620
Leu Leu Lys Thr Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys Leu			
625	630	635	640
Lys His Tyr Ser Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile Thr			
	645	650	655
Arg Asp Gln Thr Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu His			
	660	665	670
Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr Arg			
	675	680	685
Gly Ser Cys Leu Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu Cys			
	690	695	700
Leu Gly Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe Gln			
705	710	715	720
Ala Ile Asn Ala Ala Leu Gln Asn His Asn His Gln Gln Ile Ile Leu			
	725	730	735
Asp Lys Gly Met Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu Asn			
	740	745	750
His Asn Gly Glu Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala Asp			
	755	760	765
Pro Tyr Arg Val Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe Ser			
	770	775	780
Thr Arg Val Val Thr Ile Asn Arg Val Met Gly Tyr Leu Ser Ser Ala			
785	790	795	800

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
 805 810 815
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 820 825 830
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile
 835 840 845
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 850 855 860
 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 865 870 875 880
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 885 890 895
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 900 905 910
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
 915 920 925
 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 930 935 940
 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 945 950 955 960
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 965 970 975
 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 980 985 990
 Leu Asp Ser Asp Gly Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
 995 1000 1005
 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His
 1010 1015 1020
 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 1025 1030 1035
 Pro Gly Lys
 1040
 <210> 17
 <211> 1119
 <212> PRT
 <213> 人工序列
 <400> 17
 Met Ala Gln Thr Val Arg Glu Cys Ser Leu Ala Leu Leu Phe Leu Phe
 1 5 10 15

Met Trp Leu Leu Ile Lys Ala Asn Ile Asp Val Cys Lys Leu Gly Thr
 20 25 30
 Val Thr Val Gln Pro Ala Pro Val Ile Pro Leu Gly Ser Ala Ala Asn
 35 40 45
 Ile Ser Cys Ser Leu Asn Pro Lys Gln Gly Cys Ser His Tyr Pro Ser
 50 55 60
 Ser Asn Glu Leu Ile Leu Leu Lys Phe Val Asn Asp Val Leu Val Glu
 65 70 75 80
 Asn Leu His Gly Lys Lys Val His Asp His Thr Gly His Ser Ser Thr
 85 90 95
 Phe Gln Val Thr Asn Leu Ser Leu Gly Met Thr Leu Phe Val Cys Lys
 100 105 110
 Leu Asn Cys Ser Asn Ser Gln Lys Lys Pro Pro Val Pro Val Cys Gly
 115 120 125
 Val Glu Ile Ser Val Gly Val Ala Pro Glu Pro Pro Gln Asn Ile Ser
 130 135 140
 Cys Val Gln Glu Gly Glu Asn Gly Thr Val Ala Cys Ser Trp Asn Ser
 145 150 155 160
 Gly Lys Val Thr Tyr Leu Lys Thr Asn Tyr Thr Leu Gln Leu Ser Gly
 165 170 175
 Pro Asn Asn Leu Thr Cys Gln Lys Gln Cys Phe Ser Asp Asn Arg Gln
 180 185 190
 Asn Cys Asn Arg Leu Asp Leu Gly Ile Asn Leu Ser Pro Asp Leu Ala
 195 200 205
 Glu Ser Arg Phe Ile Val Arg Val Thr Ala Ile Asn Asp Leu Gly Asn
 210 215 220
 Ser Ser Ser Leu Pro His Thr Phe Thr Phe Leu Asp Ile Val Ile Pro
 225 230 235 240
 Leu Pro Pro Trp Asp Ile Arg Ile Asn Phe Leu Asn Ala Ser Gly Ser
 245 250 255
 Arg Gly Thr Leu Gln Trp Glu Asp Glu Gly Gln Val Val Leu Asn Gln
 260 265 270
 Leu Arg Tyr Gln Pro Leu Asn Ser Thr Ser Trp Asn Met Val Asn Ala
 275 280 285
 Thr Asn Ala Lys Gly Lys Tyr Asp Leu Arg Asp Leu Arg Pro Phe Thr
 290 295 300
 Glu Tyr Glu Phe Gln Ile Ser Ser Lys Leu His Leu Ser Gly Gly Ser
 305 310 315 320
 Trp Ser Asn Trp Ser Glu Ser Leu Arg Thr Arg Thr Pro Glu Glu Glu

Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn Ser
 645 650 655
 Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly Gly
 660 665 670
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Val Ile
 675 680 685
 Pro Val Ser Gly Pro Ala Arg Cys Leu Ser Gln Ser Arg Asn Leu Leu
 690 695 700
 Lys Thr Thr Asp Asp Met Val Lys Thr Ala Arg Glu Lys Leu Lys His
 705 710 715 720
 Tyr Ser Cys Thr Ala Glu Asp Ile Asp His Glu Asp Ile Thr Arg Asp
 725 730 735
 Gln Thr Ser Thr Leu Lys Thr Cys Leu Pro Leu Glu Leu His Lys Asn
 740 745 750
 Glu Ser Cys Leu Ala Thr Arg Glu Thr Ser Ser Thr Thr Arg Gly Ser
 755 760 765
 Cys Leu Pro Pro Gln Lys Thr Ser Leu Met Met Thr Leu Cys Leu Gly
 770 775 780
 Ser Ile Tyr Glu Asp Leu Lys Met Tyr Gln Thr Glu Phe Gln Ala Ile
 785 790 795 800
 Asn Ala Ala Leu Gln Asn His Asn His Gln Gln Ile Ile Leu Asp Lys
 805 810 815
 Gly Met Leu Val Ala Ile Asp Glu Leu Met Gln Ser Leu Asn His Asn
 820 825 830
 Gly Glu Thr Leu Arg Gln Lys Pro Pro Val Gly Glu Ala Asp Pro Tyr
 835 840 845
 Arg Val Lys Met Lys Leu Cys Ile Leu Leu His Ala Phe Ser Thr Arg
 850 855 860
 Val Val Thr Ile Asn Arg Val Met Gly Tyr Leu Ser Ser Ala Gly Gly
 865 870 875 880
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys Thr
 885 890 895
 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 900 905 910
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Gln Leu Met Ile Ser Arg
 915 920 925
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 930 935 940
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala

945 950 955 960
 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 965 970 975
 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 980 985 990
 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
 995 1000 1005
 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
 1010 1015 1020
 Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 1025 1030 1035
 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 1040 1045 1050
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 1055 1060 1065
 Pro Val Leu Asp Ser Asp Gly Ser Phe Leu Tyr Ser Lys Leu Thr
 1070 1075 1080
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 1085 1090 1095
 Val Leu His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 1100 1105 1110
 Ser Leu Ser Pro Gly Lys
 1115
 <210> 18
 <211> 834
 <212> PRT
 <213> 人工序列
 <400> 18
 Met Asp Met Met Gly Leu Ala Gly Thr Ser Lys His Ile Thr Phe Leu
 1 5 10 15
 Leu Leu Cys Gln Leu Gly Ala Ser Gly Pro Gly Asp Gly Cys Cys Val
 20 25 30
 Glu Lys Thr Ser Phe Pro Glu Gly Ala Ser Gly Ser Pro Leu Gly Pro
 35 40 45
 Arg Asn Leu Ser Cys Tyr Arg Val Ser Lys Thr Asp Tyr Glu Cys Ser
 50 55 60
 Trp Gln Tyr Asp Gly Pro Glu Asp Asn Val Ser His Val Leu Trp Cys
 65 70 75 80
 Cys Phe Val Pro Pro Asn His Thr His Thr Gly Gln Glu Arg Cys Arg

	85	90	95
Tyr Phe Ser Ser Gly Pro Asp Arg Thr Val Gln Phe Trp Glu Gln Asp			
	100	105	110
Gly Ile Pro Val Leu Ser Lys Val Asn Phe Trp Val Glu Ser Arg Leu			
	115	120	125
Gly Asn Arg Thr Met Lys Ser Gln Lys Ile Ser Gln Tyr Leu Tyr Asn			
	130	135	140
Trp Thr Lys Thr Thr Pro Pro Leu Gly His Ile Lys Val Ser Gln Ser			
145	150	155	160
His Arg Gln Leu Arg Met Asp Trp Asn Val Ser Glu Glu Ala Gly Ala			
	165	170	175
Glu Val Gln Phe Arg Arg Arg Met Pro Thr Thr Asn Trp Thr Leu Gly			
	180	185	190
Asp Cys Gly Pro Gln Val Asn Ser Gly Ser Gly Val Leu Gly Asp Ile			
	195	200	205
Arg Gly Ser Met Ser Glu Ser Cys Leu Cys Pro Ser Glu Asn Met Ala			
	210	215	220
Gln Glu Ile Gln Ile Arg Arg Arg Arg Arg Leu Ser Ser Gly Ala Pro			
225	230	235	240
Gly Gly Pro Trp Ser Asp Trp Ser Met Pro Val Cys Val Pro Pro Glu			
	245	250	255
Val Leu Pro Gly Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg			
	260	265	270
Thr Ala Gly Gly Gly Gly Ser Met Trp Glu Leu Glu Lys Asp Val Tyr			
	275	280	285
Val Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn			
	290	295	300
Leu Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp			
305	310	315	320
Gln Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val			
	325	330	335
Lys Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu			
	340	345	350
Thr Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile			
	355	360	365
Trp Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys			
	370	375	380
Cys Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val			
385	390	395	400

Gln Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser
 405 410 415
 Pro Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu
 420 425 430
 Lys Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys
 435 440 445
 Gln Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu
 450 455 460
 Leu Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr
 465 470 475 480
 Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu
 485 490 495
 Gln Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr
 500 505 510
 Pro Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe
 515 520 525
 Val Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly
 530 535 540
 Cys Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val
 545 550 555 560
 Gln Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr
 565 570 575
 Asn Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser
 580 585 590
 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
 595 600 605
 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
 610 615 620
 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 625 630 635 640
 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 645 650 655
 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 660 665 670
 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 675 680 685
 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 690 695 700
 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

705		710		715		720
Lys Thr Ile Ser	Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr					
	725		730		735	
Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu						
	740		745		750	
Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp						
	755		760		765	
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val						
	770		775		780	
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp						
785		790		795		800
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His						
	805		810		815	
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro						
	820		825		830	
Gly Lys						
<210> 19						
<211> 792						
<212> PRT						
<213> 人工序列						
<400> 19						
Met Ala Gln Thr Val Arg Glu Cys Ser Leu Ala Leu Leu Phe Leu Phe						
1	5		10		15	
Met Trp Leu Leu Ile Lys Ala Asn Ile Asp Val Cys Lys Leu Gly Thr						
	20		25		30	
Val Thr Val Gln Pro Ala Pro Val Ile Pro Leu Gly Ser Ala Ala Asn						
	35		40		45	
Ile Ser Cys Ser Leu Asn Pro Lys Gln Gly Cys Ser His Tyr Pro Ser						
50		55		60		
Ser Asn Glu Leu Ile Leu Leu Lys Phe Val Asn Asp Val Leu Val Glu						
65		70		75		80
Asn Leu His Gly Lys Lys Val His Asp His Thr Gly His Ser Ser Thr						
	85		90		95	
Phe Gln Val Thr Asn Leu Ser Leu Gly Met Thr Leu Phe Val Cys Lys						
	100		105		110	
Leu Asn Cys Ser Asn Ser Gln Lys Lys Pro Pro Val Pro Val Cys Gly						
	115		120		125	
Val Glu Ile Ser Val Gly Val Ala Pro Glu Pro Pro Gln Asn Ile Ser						
130		135		140		

Cys Val Gln Glu Gly Glu Asn Gly Thr Val Ala Cys Ser Trp Asn Ser
 145 150 155 160
 Gly Lys Val Thr Tyr Leu Lys Thr Asn Tyr Thr Leu Gln Leu Ser Gly
 165 170 175
 Pro Asn Asn Leu Thr Cys Gln Lys Gln Cys Phe Ser Asp Asn Arg Gln
 180 185 190
 Asn Cys Asn Arg Leu Asp Leu Gly Ile Asn Leu Ser Pro Asp Leu Ala
 195 200 205
 Glu Ser Arg Phe Ile Val Arg Val Thr Ala Ile Asn Asp Leu Gly Asn
 210 215 220
 Ser Ser Ser Leu Pro His Thr Phe Thr Phe Leu Asp Ile Val Ile Pro
 225 230 235 240
 Leu Pro Pro Trp Asp Ile Arg Ile Asn Phe Leu Asn Ala Ser Gly Ser
 245 250 255
 Arg Gly Thr Leu Gln Trp Glu Asp Glu Gly Gln Val Val Leu Asn Gln
 260 265 270
 Leu Arg Tyr Gln Pro Leu Asn Ser Thr Ser Trp Asn Met Val Asn Ala
 275 280 285
 Thr Asn Ala Lys Gly Lys Tyr Asp Leu Arg Asp Leu Arg Pro Phe Thr
 290 295 300
 Glu Tyr Glu Phe Gln Ile Ser Ser Lys Leu His Leu Ser Gly Gly Ser
 305 310 315 320
 Trp Ser Asn Trp Ser Glu Ser Leu Arg Thr Arg Thr Pro Glu Glu Glu
 325 330 335
 Pro Gly Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg Thr Ala
 340 345 350
 Gly Gly Gly Gly Ser Arg Val Ile Pro Val Ser Gly Pro Ala Arg Cys
 355 360 365
 Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val Lys
 370 375 380
 Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp Ile
 385 390 395 400
 Asp His Glu Asp Ile Thr Arg Asp Gln Thr Ser Thr Leu Lys Thr Cys
 405 410 415
 Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu
 420 425 430
 Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr Ser
 435 440 445
 Leu Met Met Thr Leu Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys Met

450	455	460
Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala Ala Leu Gln Asn His Asn		
465	470	475
His Gln Gln Ile Ile Leu Asp Lys Gly Met Leu Val Ala Ile Asp Glu		
	485	490
Leu Met Gln Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gln Lys Pro		
	500	505
Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys Ile		
	515	520
Leu Leu His Ala Phe Ser Thr Arg Val Val Thr Ile Asn Arg Val Met		
	530	535
Gly Tyr Leu Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser		
545	550	555
Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala		
	565	570
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro		
	580	585
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val		
	595	600
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val		
	610	615
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln		
625	630	635
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln		
	645	650
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala		
	660	665
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro		
	675	680
Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr		
	690	695
Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser		
705	710	715
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr		
	725	730
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val		
	740	745
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe		
	755	760
		765

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 770 775 780
 Ser Leu Ser Leu Ser Pro Gly Lys
 785 790
 <210> 20
 <211> 834
 <212> PRT
 <213> 人工序列
 <400> 20
 Met Asp Met Met Gly Leu Ala Gly Thr Ser Lys His Ile Thr Phe Leu
 1 5 10 15
 Leu Leu Cys Gln Leu Gly Ala Ser Gly Pro Gly Asp Gly Cys Cys Val
 20 25 30
 Glu Lys Thr Ser Phe Pro Glu Gly Ala Ser Gly Ser Pro Leu Gly Pro
 35 40 45
 Arg Asn Leu Ser Cys Tyr Arg Val Ser Lys Thr Asp Tyr Glu Cys Ser
 50 55 60
 Trp Gln Tyr Asp Gly Pro Glu Asp Asn Val Ser His Val Leu Trp Cys
 65 70 75 80
 Cys Phe Val Pro Pro Asn His Thr His Thr Gly Gln Glu Arg Cys Arg
 85 90 95
 Tyr Phe Ser Ser Gly Pro Asp Arg Thr Val Gln Phe Trp Glu Gln Asp
 100 105 110
 Gly Ile Pro Val Leu Ser Lys Val Asn Phe Trp Val Glu Ser Arg Leu
 115 120 125
 Gly Asn Arg Thr Met Lys Ser Gln Lys Ile Ser Gln Tyr Leu Tyr Asn
 130 135 140
 Trp Thr Lys Thr Thr Pro Pro Leu Gly His Ile Lys Val Ser Gln Ser
 145 150 155 160
 His Arg Gln Leu Arg Met Asp Trp Asn Val Ser Glu Glu Ala Gly Ala
 165 170 175
 Glu Val Gln Phe Arg Arg Arg Met Pro Thr Thr Asn Trp Thr Leu Gly
 180 185 190
 Asp Cys Gly Pro Gln Val Asn Ser Gly Ser Gly Val Leu Gly Asp Ile
 195 200 205
 Arg Gly Ser Met Ser Glu Ser Cys Leu Cys Pro Ser Glu Asn Met Ala
 210 215 220
 Gln Glu Ile Gln Ile Arg Arg Arg Arg Arg Leu Ser Ser Gly Ala Pro
 225 230 235 240

Gly Gly Pro Trp Ser Asp Trp Ser Met Pro Val Cys Val Pro Pro Glu
 245 250 255
 Val Leu Pro Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg
 260 265 270
 Thr Ala Gly Gly Gly Ser Met Trp Glu Leu Glu Lys Asp Val Tyr
 275 280 285
 Val Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn
 290 295 300
 Leu Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp
 305 310 315 320
 Gln Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val
 325 330 335
 Lys Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu
 340 345 350
 Thr Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile
 355 360 365
 Trp Ser Thr Glu Ile Leu Lys Asn Phe Lys Asn Lys Thr Phe Leu Lys
 370 375 380
 Cys Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val
 385 390 395 400
 Gln Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Ser
 405 410 415
 Pro Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu
 420 425 430
 Lys Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys
 435 440 445
 Gln Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu
 450 455 460
 Leu Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr
 465 470 475 480
 Ser Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu
 485 490 495
 Gln Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr
 500 505 510
 Pro Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe
 515 520 525
 Val Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly
 530 535 540
 Cys Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val

545		550		555		560
Gln Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr						
		565		570		575
Asn Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser						
		580		585		590
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp						
		595		600		605
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly						
		610		615		620
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile						
625		630		635		640
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu						
		645		650		655
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His						
		660		665		670
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg						
		675		680		685
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys						
		690		695		700
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu						
705		710		715		720
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr						
		725		730		735
Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu						
		740		745		750
Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp						
		755		760		765
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val						
		770		775		780
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp						
785		790		795		800
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His						
		805		810		815
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro						
		820		825		830
Gly Lys						
<210> 21						
<211> 457						
<212> PRT						

<213> 人工序列

<400> 21

```

Met Cys Gln Ser Arg Tyr Leu Leu Phe Leu Ala Thr Leu Ala Leu Leu
1           5           10           15
Asn His Leu Ser Leu Ala Arg Val Ile Pro Val Ser Gly Pro Ala Arg
          20           25           30
Cys Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val
          35           40           45
Lys Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp
          50           55           60
Ile Asp His Glu Asp Ile Thr Arg Asp Gln Thr Ser Thr Leu Lys Thr
65           70           75           80
Cys Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg
          85           90           95
Glu Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr
          100          105          110
Ser Leu Met Met Thr Leu Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys
          115          120          125
Met Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala Ala Leu Gln Asn His
          130          135          140
Asn His Gln Gln Ile Ile Leu Asp Lys Gly Met Leu Val Ala Ile Asp
145           150           155           160
Glu Leu Met Gln Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gln Lys
          165          170          175
Pro Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys
          180          185          190
Ile Leu Leu His Ala Phe Ser Thr Arg Val Val Thr Ile Asn Arg Val
          195          200          205
Met Gly Tyr Leu Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly
          210          215          220
Ser Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro
225           230           235           240
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
          245          250          255
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
          260          265          270
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
          275          280          285
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

```

290	295	300																	
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His																			
305	310	315	320																
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys																			
	325	330	335																
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln																			
	340	345	350																
Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu																			
	355	360	365																
Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro																			
370	375	380																	
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn																			
385	390	395	400																
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu																			
	405	410	415																
Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val																			
	420	425	430																
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln																			
	435	440	445																
Lys Ser Leu Ser Leu Ser Pro Gly Lys																			
450	455																		
<210> 22																			
<211> 577																			
<212> PRT																			
<213> 人工序列																			
<400> 22																			
Met Cys Pro Gln Lys Leu Thr Ile Ser Trp Phe Ala Ile Val Leu Leu																			
1	5	10	15																
Val Ser Pro Leu Met Ala Met Trp Glu Leu Glu Lys Asp Val Tyr Val																			
	20	25	30																
Val Glu Val Asp Trp Thr Pro Asp Ala Pro Gly Glu Thr Val Asn Leu																			
	35	40	45																
Thr Cys Asp Thr Pro Glu Glu Asp Asp Ile Thr Trp Thr Ser Asp Gln																			
	50	55	60																
Arg His Gly Val Ile Gly Ser Gly Lys Thr Leu Thr Ile Thr Val Lys																			
65	70	75	80																
Glu Phe Leu Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Thr																			
	85	90	95																
Leu Ser His Ser His Leu Leu Leu His Lys Lys Glu Asn Gly Ile Trp																			

100	105	110
Ser Thr Glu Ile Leu Lys Asn Phe	Lys Asn Lys Thr Phe Leu Lys Cys	
115	120	125
Glu Ala Pro Asn Tyr Ser Gly Arg Phe Thr Cys Ser Trp Leu Val Gln		
130	135	140
Arg Asn Met Asp Leu Lys Phe Asn Ile Lys Ser Ser Ser Ser Pro		
145	150	155
Asp Ser Arg Ala Val Thr Cys Gly Met Ala Ser Leu Ser Ala Glu Lys		
165	170	175
Val Thr Leu Asp Gln Arg Asp Tyr Glu Lys Tyr Ser Val Ser Cys Gln		
180	185	190
Glu Asp Val Thr Cys Pro Thr Ala Glu Glu Thr Leu Pro Ile Glu Leu		
195	200	205
Ala Leu Glu Ala Arg Gln Gln Asn Lys Tyr Glu Asn Tyr Ser Thr Ser		
210	215	220
Phe Phe Ile Arg Asp Ile Ile Lys Pro Asp Pro Pro Lys Asn Leu Gln		
225	230	235
Met Lys Pro Leu Lys Asn Ser Gln Val Glu Val Ser Trp Glu Tyr Pro		
245	250	255
Asp Ser Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Lys Phe Phe Val		
260	265	270
Arg Ile Gln Arg Lys Lys Glu Lys Met Lys Glu Thr Glu Glu Gly Cys		
275	280	285
Asn Gln Lys Gly Ala Phe Leu Val Glu Lys Thr Ser Thr Glu Val Gln		
290	295	300
Cys Lys Gly Gly Asn Val Cys Val Gln Ala Gln Asp Arg Tyr Tyr Asn		
305	310	315
Ser Ser Cys Ser Lys Trp Ala Cys Val Pro Cys Arg Val Arg Ser Gly		
325	330	335
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Lys		
340	345	350
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro		
355	360	365
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser		
370	375	380
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp		
385	390	395
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn		
405	410	415

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
 420 425 430
 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
 435 440 445
 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
 450 455 460
 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
 465 470 475 480
 Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp
 485 490 495
 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
 500 505 510
 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
 515 520 525
 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
 530 535 540
 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
 545 550 555 560
 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
 565 570 575

Lys

<210> 23

<211> 792

<212> PRT

<213> 人工序列

<400> 23

Met Ala Gln Thr Val Arg Glu Cys Ser Leu Ala Leu Leu Phe Leu Phe
 1 5 10 15
 Met Trp Leu Leu Ile Lys Ala Asn Ile Asp Val Cys Lys Leu Gly Thr
 20 25 30
 Val Thr Val Gln Pro Ala Pro Val Ile Pro Leu Gly Ser Ala Ala Asn
 35 40 45
 Ile Ser Cys Ser Leu Asn Pro Lys Gln Gly Cys Ser His Tyr Pro Ser
 50 55 60
 Ser Asn Glu Leu Ile Leu Leu Lys Phe Val Asn Asp Val Leu Val Glu
 65 70 75 80
 Asn Leu His Gly Lys Lys Val His Asp His Thr Gly His Ser Ser Thr
 85 90 95
 Phe Gln Val Thr Asn Leu Ser Leu Gly Met Thr Leu Phe Val Cys Lys

100	105	110
Leu Asn Cys Ser Asn Ser Gln Lys Lys Pro Pro Val Pro Val Cys Gly		
115	120	125
Val Glu Ile Ser Val Gly Val Ala Pro Glu Pro Pro Gln Asn Ile Ser		
130	135	140
Cys Val Gln Glu Gly Glu Asn Gly Thr Val Ala Cys Ser Trp Asn Ser		
145	150	155
Gly Lys Val Thr Tyr Leu Lys Thr Asn Tyr Thr Leu Gln Leu Ser Gly		
165	170	175
Pro Asn Asn Leu Thr Cys Gln Lys Gln Cys Phe Ser Asp Asn Arg Gln		
180	185	190
Asn Cys Asn Arg Leu Asp Leu Gly Ile Asn Leu Ser Pro Asp Leu Ala		
195	200	205
Glu Ser Arg Phe Ile Val Arg Val Thr Ala Ile Asn Asp Leu Gly Asn		
210	215	220
Ser Ser Ser Leu Pro His Thr Phe Thr Phe Leu Asp Ile Val Ile Pro		
225	230	235
Leu Pro Pro Trp Asp Ile Arg Ile Asn Phe Leu Asn Ala Ser Gly Ser		
245	250	255
Arg Gly Thr Leu Gln Trp Glu Asp Glu Gly Gln Val Val Leu Asn Gln		
260	265	270
Leu Arg Tyr Gln Pro Leu Asn Ser Thr Ser Trp Asn Met Val Asn Ala		
275	280	285
Thr Asn Ala Lys Gly Lys Tyr Asp Leu Arg Asp Leu Arg Pro Phe Thr		
290	295	300
Glu Tyr Glu Phe Gln Ile Ser Ser Lys Leu His Leu Ser Gly Gly Ser		
305	310	315
Trp Ser Asn Trp Ser Glu Ser Leu Arg Thr Arg Thr Pro Glu Glu Glu		
325	330	335
Pro Gly Gly Gly Gly Ser Ser Gly Arg Ser Glu Asn Ile Arg Thr Ala		
340	345	350
Gly Gly Gly Gly Ser Arg Val Ile Pro Val Ser Gly Pro Ala Arg Cys		
355	360	365
Leu Ser Gln Ser Arg Asn Leu Leu Lys Thr Thr Asp Asp Met Val Lys		
370	375	380
Thr Ala Arg Glu Lys Leu Lys His Tyr Ser Cys Thr Ala Glu Asp Ile		
385	390	395
Asp His Glu Asp Ile Thr Arg Asp Gln Thr Ser Thr Leu Lys Thr Cys		
405	410	415

Leu Pro Leu Glu Leu His Lys Asn Glu Ser Cys Leu Ala Thr Arg Glu
 420 425 430
 Thr Ser Ser Thr Thr Arg Gly Ser Cys Leu Pro Pro Gln Lys Thr Ser
 435 440 445
 Leu Met Met Thr Leu Cys Leu Gly Ser Ile Tyr Glu Asp Leu Lys Met
 450 455 460
 Tyr Gln Thr Glu Phe Gln Ala Ile Asn Ala Ala Leu Gln Asn His Asn
 465 470 475 480
 His Gln Gln Ile Ile Leu Asp Lys Gly Met Leu Val Ala Ile Asp Glu
 485 490 495
 Leu Met Gln Ser Leu Asn His Asn Gly Glu Thr Leu Arg Gln Lys Pro
 500 505 510
 Pro Val Gly Glu Ala Asp Pro Tyr Arg Val Lys Met Lys Leu Cys Ile
 515 520 525
 Leu Leu His Ala Phe Ser Thr Arg Val Val Thr Ile Asn Arg Val Met
 530 535 540
 Gly Tyr Leu Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 545 550 555 560
 Gly Gly Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 565 570 575
 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
 580 585 590
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 595 600 605
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 610 615 620
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 625 630 635 640
 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 645 650 655
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 660 665 670
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 675 680 685
 Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 690 695 700
 Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser
 705 710 715 720
 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr

				725					730					735	
Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Val
				740					745					750	
Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe
				755					760					765	
Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys
				770					775					780	
Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys								
				785										790	




图1




图2




图3




图4




图5




图6




图7





图8

A



B






图9


A




B



C



D







图10








图11


A




B




C




D



E



F



G




图12